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Abstract  54 
This phase 2 trial evaluated 3 low-dose intensity subcutaneous bortezomib-based treatments in 55 
patients ≥75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous 56 
bortezomib plus oral prednisone (VP, N=51) or VP plus cyclophosphamide (VCP, N=51) or VP plus  57 
melphalan (VMP, N=50), followed by bortezomib maintenance, and half of the patients were frail. 58 
Response rate was 64% with VP, 67% with VCP and 86% with VMP, very good partial response 59 
rate or better was 26%, 28.5% and 49%, respectively. Median PFS was 14.0, 15.2 and 17.1 and 2-60 
year OS was 60%, 70% and 76%, in VP, VCP, VMP respectively. At least one drug-related grade 61 
≥3 non-hematologic adverse event (AE) occurred in 22% of VP, 37% of VCP and 33% of VMP 62 
patients; the discontinuation rate for AEs was 12%, 14% and 20% and the 6-month rate of toxicity-63 
related deaths was 4%, 4% and 8%, respectively. The most common grade ≥3 AEs included 64 
infections (8-20%), constitutional (10-14%) and cardiovascular events (4-12%); peripheral 65 
neuropathy was limited (4-6%). Bortezomib maintenance was effective and feasible.  66 
VP, VCP and VMP regimens demonstrated no substantial difference. Yet, toxicity was higher with 67 
VMP, suggesting that a two-drug combination followed by maintenance should be preferred in frail 68 
patients.  69 
 70 
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 77 
 78 
4 
 
Introduction  79 
In recent years, the introduction of novel agents such as immunomodulatory drugs and the 80 
proteasome inhibitor bortezomib, associated with standard chemotherapy, has changed the 81 
management of multiple myeloma and extended survival.1 Data from the SEER registry showed a 82 
significant trend toward a better 5-year survival for patients diagnosed between 2003-2007, 83 
whereas no survival improvement was seen in older patients (≥65 years).2  84 
The global population is rapidly aging. The proportion of the population aged 65 years or over is 85 
expected to increase in all European countries, from 17.08% in 2008 to 29.95% in 2060; in 86 
particular, the population aged 80 years or over is expected to almost triple.3  87 
Approximately one third of patients with myeloma at diagnosis are older than 75 years and at least 88 
30% are frail, because of the presence of concomitant disease, abnormal laboratory test results 89 
and symptoms or signs of disability, that may complicate the presentation and management of 90 
myeloma.4,5 Although the majority of myeloma diagnoses and myeloma-related deaths occur in 91 
subjects over 65 years, elderly frail patients are not fully characterized and they are 92 
underrepresented in clinical trials. Thus, frail patients usually receive regimens tested in fit patients, 93 
which may be too toxic for them and cause early treatment discontinuation, low efficacy and 94 
impaired quality of life.  95 
Today, bortezomib-melphalan-prednisone (VMP) and melphalan-prednisone-thalidomide (MPT) 96 
are the reference treatments for elderly myeloma patients.6,7 Nevertheless, the efficacy of these 97 
regimens was less evident in patients aged 75 years or over. VMP induced a shorter overall 98 
survival in patients older than 75 years in comparison with younger patients (median 32.9 vs 50.7  99 
months);8 the incidence of any grade 3-4 adverse events (AEs) was 91% and bortezomib 100 
discontinuation rate due to AEs was 34%.9 Similar results have been reported with MPT: the 101 
median progression-free survival (PFS) of patients over 75 years (10 months with MPT and 6 102 
months with MP) was shorter compared with younger patients, and no improvement was observed 103 
in overall survival (OS).10 In another trial including patients over 75 years, MPT led to a response 104 
rate of 62% and a median PFS of 24 months, but the median duration of treatment was 13.5 105 
months and 45% of patients discontinued treatment for AEs.11  106 
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Furthermore advanced age (HR 1.44, P<0.001), the occurrence of severe cardiac, gastrointestinal 107 
AEs and infections (HR 2.53, P<0.001), and drug discontinuation (HR 1.67, P=0.01) predicted a 108 
higher risk of death in newly diagnosed myeloma patients treated with melphalan-prednisone, 109 
either alone or in combination with thalidomide and/or bortezomib. This was particularly evident 110 
with the use of more complex combinations including the association of bortezomib and 111 
thalidomide. In fact, different trials did not show a substantial advantage with multi-drug regimens 112 
over less intensive combinations, since they are often associated with higher toxicity rates and 113 
worse quality of life, especially in community-based populations.12,13  114 
The morbidity associated with dexamethasone-based regimens was significantly higher than the 115 
one reported with prednisone, especially in terms of infections and gastrointestinal complications.14  116 
These findings raise the question of whether a lower dose-intensity treatment with two-drug 117 
combinations may improve tolerability, preserving efficacy, in very elderly and frail patients, and 118 
thus should be preferred to three-drug combinations.  119 
To address this question, we designed a multicenter, community-based study to examine the 120 
efficacy and safety of weekly subcutaneous bortezomib plus continuous low-dose prednisone (VP) 121 
or cyclophosphamide-prednisone (VCP) or melphalan-prednisone (VMP) in patients over 75 years 122 
of age with newly diagnosed multiple myeloma.  123 
 124 
Patients and methods 125 
Patients aged ≥75 years old (or younger with abnormal organ function), unsuitable for standard 126 
treatments or usually excluded from clinical protocols with standard inclusion/exclusion criteria, 127 
with measurable disease and a Karnofsky Performance Status (KPS) ≥50%, were enrolled.15 128 
Diagnosis of myeloma was made using standard criteria.16 Exclusion criteria included grade ≥2 129 
peripheral neuropathy; creatinine clearance <20 ml/min; absolute neutrophil count <1,000/μL; 130 
platelets <80,000/μL; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 131 
times upper limit of normal (ULN); or total bilirubin >1.5 times ULN.  132 
6 
 
All patients provided written informed consent. Review boards at each participating site approved 133 
the study, which was conducted in accordance with the Declaration of Helsinki. This trial is 134 
registered at www.clinicaltrials.gov, NCT01190787. 135 
 136 
Study design 137 
This phase 2, non-randomized study was conducted at 23 centers. Patients were enrolled in either 138 
one of the three, independent bortezomib cohorts, namely VP, or VCP, or VMP. Subjects were 139 
recruited from October 2010 to August 2012; the cut-off date was March 15, 2014.  140 
The primary objective was to determine the rate of very good partial response (VGPR) in patients 141 
with newly diagnosed multiple myeloma treated with VP, VCP and VMP regimens. 142 
Secondary objectives included safety and tolerability, overall response rates (ORR), time to 143 
response (TTR), time to progression (TTP), PFS, and overall survival (OS).  144 
 145 
Study Treatment 146 
Patients were enrolled in three cohorts of treatment with VP, VCP and VMP. Treatment consisted 147 
of nine 28-day cycles of induction therapy with subcutaneous bortezomib 1.3 mg/m2 on days 1, 8, 148 
15, 22 plus oral prednisone 50 mg every other day (VP) or VP plus oral cyclophosphamide 50 mg 149 
every other day (VCP) or plus oral melphalan 2 mg every other day (VMP); followed by 150 
maintenance with subcutaneous bortezomib on days 1, 15, until progression.  151 
Patients could receive supportive therapy including bisphosphonates, granulocyte colony-152 
stimulating factor (G-CSF), erythropoietin and transfusions, as necessary. Prophylactic acyclovir 153 
for herpes zoster was recommended.  154 
 155 
Assessments 156 
At baseline a geriatric assessment (GA) was performed. The GA consisted of three tools: Katz’s 157 
Activities of Daily Living (ADL) and Lawton’s Instrumental Activities of Daily Living (IADL) scores to 158 
assess self-care activities, tasks of household management and independence status; Charlson 159 
comorbidity index (CCI) to estimate the number and the severity of comorbidities.17,18  160 
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AEs were graded according to NCI-CTCAE version 3.0.19 Response was assessed prior to every 161 
treatment cycle. Response categories were based on the International Myeloma Working Group 162 
uniform response criteria.16  163 
 164 
Statistical methods 165 
Based on the primary objective (VGPR rate), sample size was estimated at the significance level of 166 
α =0.05, power of 80%, a null hypothesis VGPR rate of 10%, and an alternative hypothesis VGPR 167 
rate of 25%. 168 
Based on Simon’s optimal two-stage design,20 for each cohort 43 patients were required (18 169 
patients in the first phase, 25 in the second one). Assuming 15% of patients lost to follow-up, to 170 
obtain 129 response-evaluable patients, the enrollment of ~150 patients was targeted (50 per 171 
cohort). 172 
Given the non-comparative nature of the study, no formal statistical comparisons between the 3 173 
treatment cohorts were made.  174 
All patients who received at least one dose of any study drug were included in the safety analyses. 175 
The response-evaluable population was defined as a subset of the intention to treat (ITT) 176 
population with measurable disease at baseline and with at least one post baseline response 177 
assessment.  178 
OS was calculated from the start of the treatment until the date of death or the date the patient was 179 
last known to be alive. PFS was calculated from the start of the treatment until the date of disease 180 
progression or death (regardless of cause of death). Time-to-event analyses were performed with 181 
the Kaplan–Meier method.21 The analyses were performed using SAS software version 8.2 (SAS 182 
Institute). 183 
 184 
Results 185 
 186 
Patient characteristics 187 
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One-hundred-fifty-two patients were enrolled, 51 in the VP, 51 in the VCP and 50 in the VMP 188 
cohorts. Patient disposition is shown in Figure 1. The median follow-up from enrolment was 27.2 189 
months (range: 0–42).  190 
The median age was 78 years (range: 59–88) with 33% of patients ≥80 years of age. Overall, 27%, 191 
29% and 44% of patients had ISS stage I, II or III disease, respectively. Eighteen percent of 192 
patients had high-risk myeloma, defined by the presence of any of t(4;14), t(14;16), or del17p13 by 193 
FISH. According to the frailty scoring system,4 based on age, comorbidities, cognitive and physical 194 
conditions, 3 groups of patients were identified: fit (score=0, 16%); intermediate (score=1, 30%), 195 
and frail (score≥2, 54%) (Appendix).  196 
Baseline characteristics were similar between the treatment cohorts (Table 1), except for the VP 197 
group, where a higher proportion of patients ≥80 years (41%), frail (72%) and with ISS stage III 198 
(53%) was observed.  199 
 200 
Efficacy 201 
One-hundred-forty-eight out of 152 patients started treatment. Four patients did not start treatment 202 
for withdrawal of consent (2 patients), lost to follow-up (1 patient) and patient condition (1 patient) 203 
(Figure 1). 204 
The median number of cycles administered was 9 (range: 1–9), with similar distribution across 205 
groups. The median time on therapy was approximately 11 months in all treatment groups.  206 
Ninety-three patients across the 3 cohorts completed all 9 cycles of induction, and 79 patients 207 
started maintenance as planned.  208 
Overall 148 patients could be evaluated for response. After induction, the ORR was 64% with VP, 209 
67% with VCP, and 86% with VMP, including a VGPR or better of 26%, 28.5%, and 49%, and a 210 
complete response (CR)/ stringent CR (sCR) of 8%, 2% and 14% in the three cohorts, respectively 211 
(Table 2). The median time to at least a VGPR was 5.7 months.  212 
The median PFS was 14.0, 15.2, and 17.1 months, and the 2-year OS estimate was 60%, 70%, 213 
76% for the VP, VCP and VMP groups, respectively. (Figure 2) The median PFS was 14.1 months 214 
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for patients <80 years and 16.1 for patients ≥80 years, and the respective 2-year OS rates were 215 
70% and 67%. 216 
We examined the impact of frailty on outcome. Among patients enrolled in the VP group, the 217 
majority were frail (72%) and ≥80 years (41%). More fit patients received triplet regimens. In the 218 
overall population, the median PFS was 22.4, 15.2 and 13.8 months, and the 2-year OS was 84%, 219 
76% and 60% in fit, intermediate and frail patients, respectively.  220 
 221 
Safety 222 
One-hundred-forty-eight patients could be evaluated for toxicity. Hematological toxicity was 223 
infrequent; the rate of at least one grade ≥ 3 hematologic AE was 6% with VP, 8% with VCP and 224 
10% with VMP groups and they were considered drug-related according to investigators’ opinion. 225 
Overall, grade 3 or higher thrombocytopenia was observed in 2% of patients.   226 
The incidence of at least one drug-related grade ≥ 3 non-hematologic AE was 22% with VP, 37% 227 
with VCP and 33% with VMP. The most common toxicities were infections (8-14%) mostly 228 
pulmonary; constitutional (6-10%) mostly fatigue; and cardiac events (4-8%), mostly heart failure. 229 
Grade ≥ 3 peripheral neuropathy occurred in 8 patients (5%) (Table 3). Five solid second primary 230 
malignancies (pancreas, bowel, breast, liver and lung) were reported: 2 cases were diagnosed 231 
within 6 months from the start of myeloma therapy and 3 after more than 17 months.  232 
At least one drug-related non-hematologic serious AE (SAE) was reported in 8%, 8% and 20% in 233 
the VP, VCP and VMP groups. The most frequent SAEs were cardiologic events (heart failure in 4 234 
patients and atrial fibrillation in 2 patients) and infections (bronchitis in 2 patients, pneumonia in 5 235 
patients and sepsis in 1 patient).  236 
Twelve percent of patients in the VP, 14% in the VCP, and 20% in the VMP groups discontinued 237 
treatment due to AEs.  238 
Fifteen, 13 and 10 deaths occurred during induction treatment in the VP, VCP and VMP groups 239 
respectively; among them 27%, 31% and 50% were due to AEs. Toxicity-related deaths within 60 240 
days occurred in 3.4% of the patients, mainly due to infections (2 patients) and cardiovascular 241 
events (3 patients). Within 6 months of start of therapy, 15 patients (10%) died for any cause, and 242 
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8 (5%) due to AEs: infections (4 patients), cardiovascular events (3 patients) and one second 243 
cancer (pancreas).  244 
At least one drug-related SAE was reported in 13% of frail patients and none in fit ones. The drop-245 
out rate during induction was higher in frail patients (55%) as compared with fit ones (28%). The 246 
discontinuation rate due to AEs was 26% in frail patients and 8% in fit ones. The majority of early 247 
deaths due to toxicity within 6 months of the start of therapy occurred in frail patients (5/6, 83%).   248 
 249 
Maintenance 250 
Seventy-nine patients started maintenance, 25 in the VP, 25 in the VCP and 29 in the VMP groups.  251 
After a median follow-up of 18 months (range 1-43 months) from the initiation of maintenance, an 252 
improvement in the depth of response was observed in 14 patients (18%): 1 patient in CR 253 
upgraded to sCR, 5 patients in VGPR upgraded to CR/sCR, 4 patients in PR upgraded to either 254 
CR or VGCR, and 4 patients in SD upgraded to VGPR or PR. Overall, 51% of patients had a 255 
stability of response. Response to maintenance therapy was not influenced by the previous 256 
induction regimen. 257 
The median PFS from the start of maintenance was 27.7 months; the 2-year OS estimate was 88% 258 
(Figure 2).  259 
Approximately half of frail patients enrolled in the trial started maintenance. No significant 260 
difference in PFS was observed among fit, intermediate and frail patients.   261 
No grade 3 or higher hematologic AEs related to bortezomib were reported. At least one grade ≥ 3 262 
non-hematologic AE was seen in 16% of the patients; only 7.5% of them were considered related 263 
to the study drugs. The most frequent drug-related AEs were infections. The rate of discontinuation 264 
due to AEs was 14%.  265 
 266 
Discussion 267 
To our knowledge, this is the first prospective study assessing bortezomib-based treatments in 268 
very elderly (≥75 years) and frail patients with comorbidities and/or disabilities, who are usually 269 
excluded from clinical trials. 270 
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This study shows that low dose intensity bortezomib-based regimens are well tolerated and are 271 
effective in a community-based setting, with similar efficacy between the doublet VP and the 272 
triplets VCP and VMP. Toxicities, discontinuation rate and early deaths due to toxicity were higher 273 
in the VMP group, particularly in frail patients. 274 
Our data compares favorably with the US community-based, phase 3b randomized, UPFRONT 275 
trial, which compared bortezomib-dexamethasone (VD), bortezomib-thalidomide-dexamethasone 276 
(VTD), and bortezomib-melphalan-prednisone (VMP), followed by weekly bortezomib 277 
maintenance, in elderly patients with newly diagnosed MM.12 The median age was 73 years, 18% 278 
of patients were ≥80 years and 48% had at least one comorbidity. All three regimens demonstrated 279 
substantial activity, with an ORR of 73%, 80% and 70%, respectively, and no significant difference 280 
in median PFS (14.7 months with VD, 15.4 months with VTD and 17.3 months with VMP).  281 
Our results confirm these data, highlighting that the doublet therapy may be as effective as the 282 
triplets, considering both efficacy and treatment-related toxicities.    283 
In our study, these low dose intensity regimens were well tolerated. Only 5% of patients reported 284 
grade ≥3 neuropathy and a very low incidence of severe thrombocytopenia was observed. The use 285 
of subcutaneous once-weekly bortezomib significantly reduced peripheral neuropathy, which was 286 
reported in approximately 20% of patients treated with twice-weekly bortezomib.12 The most 287 
common AEs included infections (8%-14%) and cardiac events (4-8%), which occurred mostly in 288 
VMP patients. The incidence of infections and cardiac complications in our trial seems higher as 289 
compared to the Spanish trial in which bortezomib was administered once-weekly, but the patient 290 
populations of the two trials are not comparable (fit patients with a median age of 73 years versus 291 
frail patients with a median age of 78 years).22 Thus prophylactic antibiotics during the first 3-4 292 
months of induction and a more accurate upfront cardiac screening should be considered.    293 
In the French MPT trial designed for patients over 75 years, 45% of patients discontinued 294 
treatment for AEs.11 In the UPFRONT study, 22-28% discontinued treatment for drug-related AEs. 295 
The toxicity profile was influenced by the use of twice-weekly bortezomib, combined with 296 
thalidomide or full dose melphalan (9 mg/m2 for 4 days). In our trial bortezomib was given once-297 
weekly and melphalan at lower doses, thus producing similar responses and outcomes, but a lower 298 
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toxicity, in a comparable setting. In our study the discontinuation rate was low, from 8% to 20% in 299 
the VMP group, suggesting that a low dose intensity treatment could be an option in this subset of 300 
patients, to avoid early discontinuation.    301 
Concerning early deaths, 5% of patients died due to AEs and 3% due to progressive disease in the 302 
first 6 months from start of therapy. The 2-fold higher risk of early deaths for toxicity as compared 303 
to disease progression confirms the need for a careful assessment of frail patients who may benefit 304 
from a gentler or even palliative approach. Furthermore the improvement in supportive therapy 305 
together with prevention, prompt recognition and treatment of complications are urgently needed to 306 
reduce the risk of deaths due to toxicity.  307 
In our trial bortezomib maintenance was associated with an improvement in response, a longer 308 
PFS and very few AEs. Furthermore, during maintenance the discontinuation rate due to any 309 
cause and particularly due to AEs, was low, indicating that the schedule of bortezomib planned in 310 
this study is feasible. Previous studies have evaluated the role of frontline continuous bortezomib-311 
based treatment.23,24 The Spanish trial including fit elderly patients, evaluated bortezomib 312 
maintenance after VMP or VTP induction, and found that VP maintenance induced a median PFS 313 
of 32 months. In our study, maintenance therapy with bortezomib resulted into a long PFS (27.7 314 
months), which is quite comparable with the PFS reported in fit patients.  315 
The benefit of a continuous treatment with lenalidomide after an alkylator-based regimen was less 316 
evident in patients older than 75 years of age;25 whereas its activity was confirmed in the 317 
continuous treatment lenalidomide-dexamethasone, irrespective of age. In our trial the beneficial 318 
effect of bortezomib maintenance was evident irrespective of age and frailty status. In this 319 
community-based setting a prolonged time without symptoms of disease progression and without 320 
major toxicities would translate into a physical and emotional benefit for the patient. Therefore the 321 
final benefit of a prolonged maintenance versus a treatment-free-interval remains still unknown. 322 
Thus it would be essential in future trials to validate this hypothesis, also through quality of life 323 
studies. 324 
Until now, advanced age was usually the only criterion to define frail patients, which sometimes led 325 
to an improper under-treatment or over-treatment of patients. In this study no difference was 326 
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observed in patients younger or older than 75 or 80 years, confirming that age is no longer 327 
sufficient to appropriately identify frail patients. As recently reported in a large analysis including 328 
also the present trial, by applying a frailty score that combines age, functional status (measured 329 
with ADL and IADL scores) and comorbidities (assessed with CCI), we were able to stratify 330 
patients into fit, intermediate and frail; of note, the latter group showed an inferior survival, a higher 331 
risk of non-hematologic AEs and treatment discontinuation.4  332 
In the current study the majority of patients were frail (54%), and the majority of frail and older 333 
patients (≥80 years) were enrolled in the VP group.  334 
The main limit of this non-randomized trial is that the patients were not stratified at enrolment. The 335 
unbalanced distribution of frail and older patients among the 3 treatment groups may in part 336 
explain the lower rate of response observed in the VP group. On the other hand, the standard 337 
approved treatment MPT and VMP with twice-weekly bortezomib for newly diagnosed myeloma 338 
patients induced response rates of 71% and 59%, a median PFS of 24 and 20.3 months, with a 339 
rate of treatment discontinuation for toxicity of 34%-40%, respectively.6,7 In our study, the majority 340 
of fit patients received the triplet VMP and VCP (84%); in fit patients response rate was 76%, the 341 
median PFS was 22.4 months, and the rate of treatment discontinuation for toxicity was 8%. In frail 342 
patients treated with VMP the discontinuation rate for toxicity was 29%. The shorter PFS observed 343 
in frail patients (13.8 months) may be due to the higher toxicity and treatment discontinuation, 344 
highlighting the difficulty in treating frail patients even with low dose intensity regimens. These data 345 
confirm the activity of VMP or triplet bortezomib-based treatments in fit elderly patients, which still 346 
appear too toxic for frail patients.  347 
In conclusion, the current study, with the limits of its phase 2 design, did not show a substantial 348 
advantage for the three-drug regimens. The VMP group showed significant activity, at the expense 349 
of a higher toxicity.  350 
The growing number of older adults with myeloma is increasing the need for practical strategies to 351 
recognize and appropriately manage frail patients. The efficacy and safety results, as well as the 352 
costs associated with treatment, suggest that full dose triplet combinations can be indicated in fit 353 
patients, where a good quality response and a prolonged PFS and OS are the goals of treatment. 354 
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A doublet therapy should be preferred in frail patients, where the real goals of care are stabilization 355 
of the disease, symptoms control, maintenance of quality of life and independence status, over 356 
prolonged survival. In this setting a doublet combination with subcutaneous bortezomib and low 357 
dose steroid followed by maintenance could be recommended as upfront treatment.  358 
This study represents a starting point for a prospective evaluation of two-drug regimens in frail 359 
elderly patients. 360 
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Figure legend. 491 
Figure 1. Patient disposition 492 
Figure 2. Kaplan-Meier analyses of treatment outcomes. Panel A shows Progression Free Survival 493 
from start of treatment. Panel B shows Overall Survival from start of treatment. Panel C shows 494 
Progression Free Survival from start of maintenance. Panel D shows Overall Survival from start of 495 
maintenance 496 
 497 
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 Figure 2  
Kaplan-Meier analyses of treatment outcomes 
A. Progression Free Survival from start of treatment 
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Table 1 Baseline patient characteristics 
 
Characteristics  VP 
(n=51) 
VCP 
(n=51) 
VMP 
(n=50) 
Median age, years (IQR) 78 (76-82) 77 (73-80) 78 (75-81) 
Age ≥ 80 years, n (%) 21 (41) 14 (27) 15 (30) 
Gender, male, n (%) 22 (43) 26 (51) 30 (60) 
Myeloma type, n (%)    
   IgG 33 (65) 30 (58) 27 (54) 
   IgA 11 (21) 10 (20) 18 (36) 
   Light chain 7 (14) 10 (20) 5 (10) 
   Other 0 1 (2) 0 
ISS stage, n (%)    
   I 12 (23.5) 15 (29) 14 (28) 
   II 12 (23.5) 12 (24) 20 (40) 
   III 27 (53) 24 (47) 16 (32) 
Karnofsky performance status, n (%)    
   50-60% 5 (10) 4 (8) 3 (6) 
   70-80% 21 (41) 21 (41) 23 (46) 
   90-100% 25 (49) 26 (51) 24 (48) 
Serum creatinine >1.5 mg/dl, n (%) 15 (29) 8 (16) 12 (24) 
Creatinine clearance <60 ml/min 30 (59) 26 (51) 28 (56) 
LDH >450 u/L, % 6 (12) 6 (12) 5 (10) 
Bone disease present, % 29 (57) 28 (55) 26 (52) 
Chromosomal abnormalities    
   t(4;14) 4 (8) 0 5 (10) 
   t(14;16) 1 (2) 4 (8) 0 
   -17p13 6 (12) 7 (14) 6 (12) 
   High risk* 9 (20) 9 (19) 10 (23) 
Frailty assessment°    
   Fit                       4 (8) 13 (26) 8 (16) 
   Intermediate                  10 (20) 18 (35) 17 (34) 
   Frail                    37 (72) 20 (39) 25 (50) 
VP, bortezomib-prednisone; VCP, bortezomib-cyclophosphamide-prednisone; VMP, bortezomib-melphalan-prednisone 
*High risk defined as any of the following t(4;14), t(4;16) or -17p13 by FISH.  
° Fit defined as age<80 years, ADL= 6, IADL=8, Charlson score= 0, unfit defined as age >80 years or ADL=5, IADL=6-7, 
Charlson score=1, or frail defined as age >80 years or ADL≤4, IADL ≤5 and Charlson score ≥2. 
 
 
1 
 
Table 2 Treatment exposure and response 
Treatment exposure VP 
(n=51) 
VCP 
(n=51) 
VMP 
(n=50) 
Median follow-up, months 26.1 28.5 27.3 
Median cycles, n (range) 9 (1-9) 9 (1-9) 9 (1-9) 
Completed induction, n (%) 29 (57) 32 (63) 32 (64) 
Started maintenance, n (%) 25 (49) 25 (49) 29 (58) 
    
Best response to induction* VP 
(n=50) 
VCP 
(n=49) 
VMP 
(n=49) 
ORR (PR or better) 32 (64) 33 (67) 42 (86) 
VGPR or better 13 (26) 14 (28.5) 24 (49) 
sCR/CR 4 (8) 1 (2)  7 (14) 
VGPR 9 (18) 13 (26.5)  17 (35) 
PR 19 (38) 19 (39)  18 (37) 
SD 16 (32) 14 (28.5) 7 (14) 
PD 0 1 (2) 0 
NA 2 (4) 1 (2) 0 
    
Best response to maintenance* VP 
(n=25) 
VCP 
(n=25) 
VMP 
(n=29) 
ORR (PR or better) 13 (52) 14 (56) 24 (83) 
VGPR or better 9 (36) 9 (36) 14 (48) 
CR/sCR 5 (20) 2 (8) 8 (28) 
VGPR 4 (16) 7 (28) 6 (21) 
PR 4 (16) 5 (20) 10 (34) 
SD 7 (28) 4 (16) 3 (10) 
PD 4 (16) 5 (20) 0 
NA 1 (4) 2 (8) 2 (7) 
VP, bortezomib-prednisone; VCP, bortezomib-cyclophosphamide-prednisone; VMP, bortezomib-melphalan-prednisone; 
ORR, overall response rate; PR, partial response rate; VGPR, very good partial response; CR complete response; sCR, 
stringent complete response; SD, stable disease; PD, progressive disease; NA, not available. 
* patients starting treatment 
 
Table 3 Grade 3 or higher adverse events (during induction) 
 VP 
(n=50)
VCP 
(n=49)
VMP 
(n=49) 
Hematological AEs, n (%) 
Anemia 
   Drug-related  
4 (8) 
3 
4 (8) 
3 
3 (6) 
3 
Neutropenia 
   Drug-related 
2 (4) 
2 
1 (2) 
1 
0 
0 
Thrombocytopenia 
   Drug-related 
1 (2) 
1 
0 
0 
2 (4) 
2 
At least one hematological AE 
   Drug-related 
 
3 (6) 
 
4 (8) 
 
5 (10) 
Non-hematological AEs, n (%) 
Cardiac 
   Drug-related 
       Heart failure (related) 
       Atrial fibrillation (related) 
3 (6) 
2 
1 
1 
2 (4) 
1 
1 
0 
6 (12) 
4 
3 
1 
Gastro-hepatic 
   Drug-related 
       Diarrhea (related) 
       Constipation (related) 
2 (4) 
1 
0 
1 
2 (4) 
2 
2 
0 
1 (2) 
1 
0 
0 
Constitutional 
   Drug-related 
       Fatigue (related) 
       Edema limbs (related) 
5 (10) 
3 
0 
0 
7 (14) 
5 
3 
1 
5 (10) 
3 
0 
1 
Infections 
   Drug-related 
        Lung (related)     
4 (8) 
4 
2 
6 (12) 
5 
2 
10 (20) 
7 
4 
Investigational 
   Drug-related 
       Creatinine increased (related) 
2 (4) 
1 
0 
4 (8) 
4 
3 
2 (4) 
1 
1 
Nervous 
   Drug-related 
       Peripheral neuropathy (related) 
4 (8) 
2 
2 
6 (12) 
6 
3 
5 (10) 
3 
3 
Renal 
   Drug-related 
3 (6) 
1 
1 (2) 
1 
3 (6) 
1 
Respiratory 
   Drug-related 
       Pulmonary fibrosis (related) 
4 (8) 
3 
0 
1 (2) 
0 
0 
3 (6) 
1 
1 
Skin  
   Drug-related 
       Rash (related) 
0 
0 
0 
4 (8) 
4 
3 
1 (2) 
0 
0 
Vascular 
   Drug-related 
       Thromboembolic event (related)    
       Hypertension/hypotension (related) 
       Hematoma (related) 
3 (6) 
1 
1 
0 
0 
2 (4) 
1 
0 
0 
0 
3 (6) 
3 
0 
2 
1 
At least one non-hematological AE 
   Drug-related 
 
11 (22)
 
18 (37)
 
16 (33) 
At least one non-hematological SAE 
   Drug-related 
 
4 (8) 
 
4 (8) 
 
10 (20) 
Discontinuation rate and early death 
     Discontinuation rate due to AE (%) 12 14 20 
     Discontinuation rate due to AE in frail patients** 11 10 29 
     Early toxic deaths (%) 4 4 8 
 
AE, adverse event; SAE, serious adverse event; VP, bortezomib-prednisone; VCP, bortezomib-cyclophosphamide-
prednisone; VMP, bortezomib-melphalan-prednisone 
 
 
AEs occurred during induction. 
Drug-related AEs, according to investigator opinion.  
** The percentage is calculated on frail patients n=36 in VP, n=20 in VCP, n=24 in VMP group.  
